United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - doxazosin mesylate (unii: 86p6pqk0mu) (doxazosin - unii:nw1291f1w8) - doxazosin 2 mg - doxazosin tablets are indicated for the treatment of the signs and symptoms of bph. doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerou

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - doxazosin mesylate (unii: 86p6pqk0mu) (doxazosin - unii:nw1291f1w8) - doxazosin 1 mg - a. benign prostatic hyperplasia (bph). doxazosin mesylate tablets is indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with bph: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). doxazosin mesylate tablets may be used in all bph patients whether hypertensive or normotensive. in patients with hypertension and bph, both conditions were effectively treated with doxazosin mesylate tablets monotherapy. doxazosin mesylate tablets provides rapid improvement in symptoms and urinary flow rate in 66-71% of patients. sustained improvements with doxazosin mesylate tablets were seen in patients treated for up to 14 weeks in double-blind studies and up to 2 years in open-label studies. b. hypertension . doxazosin mesylate tablets is also indicated for the treatment of hypertension. doxazosin mesylate tablets ma

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - doxazosin mesylate (unii: 86p6pqk0mu) (doxazosin - unii:nw1291f1w8) - doxazosin 1 mg - a. benign prostatic hyperplasia (bph). doxazosin mesylate tablets is indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with bph: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). doxazosin mesylate tablets may be used in all bph patients whether hypertensive or normotensive. in patients with hypertension and bph, both conditions were effectively treated with doxazosin mesylate tablets monotherapy. doxazosin mesylate tablets provides rapid improvement in symptoms and urinary flow rate in 66-71% of patients. sustained improvements with doxazosin mesylate tablets were seen in patients treated for up to 14 weeks in double-blind studies and up to 2 years in open-label studies. b. hypertension . doxazosin mesylate tablets is also indicated for the treatment of hypertension. doxazosin mesylate tablets ma

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - doxazosin mesylate (unii: 86p6pqk0mu) (doxazosin - unii:nw1291f1w8) - doxazosin 1 mg -       doxazosin tablets are indicated for the treatment of the signs and symptoms of bph. doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). n

Canada - English - Health Canada

jamp pharma corporation - doxazosin (doxazosin mesylate) - tablet - 1mg - doxazosin (doxazosin mesylate) 1mg - alpha-adrenergic blocking agents

Canada - English - Health Canada

jamp pharma corporation - doxazosin (doxazosin mesylate) - tablet - 2mg - doxazosin (doxazosin mesylate) 2mg - alpha-adrenergic blocking agents

Canada - English - Health Canada

jamp pharma corporation - doxazosin (doxazosin mesylate) - tablet - 4mg - doxazosin (doxazosin mesylate) 4mg - alpha-adrenergic blocking agents

United States - English - NLM (National Library of Medicine)

stat rx usa - doxazosin mesylate (unii: 86p6pqk0mu) (doxazosin - unii:nw1291f1w8) - doxazosin mesylate 4 mg - doxazosin tablets are indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with bph: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). doxazosin may be used in all bph patients whether hypertensive or normotensive. in patients with hypertension and bph, both conditions were effectively treated with doxazosin monotherapy. doxazosin provides rapid improvement in symptoms and urinary flow rate in 66 to 71% of patients. sustained improvements with doxazosin were seen in patients treated for up to 14 weeks in double-blind studies and up to 2 years in open-label studies. doxazosin tablets are also indicated for the treatment of hypertension. doxazosin may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers or angiotensin-converting enzyme inhibito

United States - English - NLM (National Library of Medicine)

kv pharmaceuticals - doxazosin mesylate (unii: 86p6pqk0mu) (doxazosin - unii:nw1291f1w8) - tablet - 1 mg - a. benign prostatic hyperplasia (bph) doxazosin mesylate tablets are indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with bph: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). doxazosin mesylate tablets may be used in all bph patients whether hypertensive or normotensive. in patients with hypertension and bph, both conditions were effectively treated with doxazosin mesylate tablet monotherapy. doxazosin mesylate tablets provides rapid improvement in symptoms and urinary flow rate in 66-71% of patients. sustained improvements with doxazosin mesylate tablets were seen in patients treated for up to 14 weeks in double-blind studies and up to 2 years in open-label studies. b. hypertension doxazosin mesylate tablets are also indicated for the treatment of hypertension. doxazosin mesylate tablets may be

United States - English - NLM (National Library of Medicine)

legacy pharmaceutical packaging, llc - doxazosin mesylate (unii: 86p6pqk0mu) (doxazosin - unii:nw1291f1w8) - doxazosin 2 mg - doxazosin tablets are indicated for the treatment of the signs and symptoms of bph. doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerou